1) High Valuation 2) Loss in 1 year out of last 3 years 3) Big size 4) Pharma company 5) Another pharma company ipo is there with better valuation than this on same time.
3. PLAZA| Link| Bookmark|
March 23, 2023 6:58:54 PM
IPO Guru (2400+ Posts, 1300+ Likes)
HUGE LOSS IN F Y 2020-21 and set off in F Y 2021-22 .seems totally adjusted figure paying only MAT . seems Cooked data for passthrough sme issues as per lead managers
Avoid considering borrowings, high priced and not a direct manufacturer, but only loan licensing manufacturer (LLM). Due to LLM, revenue can be hit due to over dependency on any one Company. Profitability is less than 1%. Currently main manufacturers in Pharma are struggling to sustain, how LLMs can survive?
Save hard earned money and Simply AVOID.....AVOID.....AVOID
1. svh| Link| Bookmark|
March 23, 2023 12:33:58 PM
IPO Guru (2600+ Posts, 3700+ Likes)
Avoiding this 1. Aggresively priced like sudarshan. Infinium looks better than this and sudarshan.